SCHEMBL1852380

SCHEMBL1852380

CS(=O)(=O)[N]N1CCc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.49
KMT2A Q03164 8/20 0.49
ALDH1A1 P00352 5/20 0.49
MAPT P10636 4/20 0.49
TSHR P16473 3/20 0.49
POLB P06746 3/20 0.49
USP2 O75604 1/20 0.48
CDK4 P11802 1/20 0.48
ALOX15 P16050 1/20 0.48
CCND1 P24385 1/20 0.48
NOTUM Q6P988 1/20 0.47
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 2/20 0.44
PTK2B Q14289 1/20 0.44
ESR2 Q92731 1/20 0.44
PKM P14618 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2344277 0.79 ALDH1A1 (0.53) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL30662376 0.78 ALDH1A1 (0.57) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL2102471 0.76 KMT2A (0.58) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL9481953 0.75 ALDH1A1 (0.53) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL9481934 0.75 MEN1 (0.53) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL23131053 0.75 ALDH1A1 (0.53) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL1383224 0.74 MEN1 (0.48) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL2694560 0.73 MEN1 (0.69) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL6769554 0.71 MEN1 (0.46) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL1852381 0.71 NOTUM (0.45) MEN1KMT2AALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA MEN1 1461/4885KMT2A 2966/4885ALDH1A1 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.